



ESPEN Endorsed Recommendation

The GLIM consensus approach to diagnosis of malnutrition: A 5-year update[☆]



Tommy Cederholm^{a,b,*}, Gordon L. Jensen^{c,1}, M. Isabel T.D. Correia^d,
M. Cristina Gonzalez^e, Ryoji Fukushima^f, Veeradej Pisprasert^g, Renee Blaauw^h,
Diana Cardenas Brazⁱ, Fernando Carrasco^j, Alfonso J. Cruz Jentoft^k, Cristina Cuerda^l,
David C. Evans^m, Vanessa Fuchs-Tarlovskyⁿ, Leah Gramlich^o, Han Ping Shi^p,
Jeanette M. Hasse^q, Michael Hiesmayr^r, Naoki Hiki^s, Harriët Jager-Wittenaar^t,
Shukri Jahit^u, Anayanet Jáquez^v, Heather Keller^w, Stanislaw Klek^x, Ainsley Malone^y,
Kris M. Mogensen^z, Naoharu Mori^{aa}, Manpreet Mundi^{ab}, Maurizio Muscaritoli^{ac},
Doris Ng^{ad}, Ibolya Nyulasi^{ae,af}, Matthias Pirlich^{ag}, Stephane Schneider^{ah},
Marian de van der Schueren^{ai,aj}, Soranit Siltharm^{ak}, Pierre Singer^{al}, Alison Steiber^{am},
Kelly A. Tappenden^{an}, Jianchun Yu^{ao}, André van Gossum^{ap}, Jaw-Yuan Wang^{aq},
Marion F. Winkler^{ar}, Rocco Barazzoni^{as,1}, Charlene Compher^{at,1}

^a Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden^b Theme Inflammation & Aging, Karolinska University Hospital, Stockholm, Sweden^c Dean's Office and Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA^d Department of Surgery, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil^e Postgraduate Program in Nutrition and Food, Federal University of Pelotas, RS, Brazil^f Department of Health and Dietetics, Faculty of Health and Medical Science, Teikyo Heisei University, Tokyo, Japan^g Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand^h Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africaⁱ Nutrition Unit, Gustave Roussy, Villejuif, France^j Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile^k Servicio de Geriátrica, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain^l Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain^m Department of Surgery, OhioHealth Grant Medical Center and Ohio University, Columbus, OH, USAⁿ Clinical Nutrition Department, Hospital General de México, Mexico City, Mexico^o Department of Medicine, University of Alberta, Edmonton, Alberta, Canada^p Department of GI Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China^q Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, USA^r Center for Medical Data Science, Unit for Medical Statistics, Medical University Vienna, Vienna, Austria^s Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan^t Department of Gastroenterology and Hepatology, Dietetics, Nijmegen, The Netherlands. Research Group Healthy Ageing, Allied Health Care and Nursing, Hanze University of Applied Sciences, Groningen, the Netherlands^u National Cancer Institute, Putrajaya, Malaysia^v Pontificia Universidad Católica Madre y Maestra, Santiago, Chile^w Schlegel-UW Research Institute for Aging and Department of Kinesiology & Health Sciences, University of Waterloo, Ontario, Canada[☆] This article is co-published in Clinical Nutrition and Journal of Parenteral and Enteral Nutrition with Tommy Cederholm and Gordon L Jensen as first authors.^{*} Corresponding author. Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden.

E-mail addresses: tommy.cederholm@uu.se (T. Cederholm), gordon.jensen@med.uvm.edu (G.L. Jensen), isabeldavisoncorreia@gmail.com (M.I.T.D. Correia), cristinagbs@hotmail.com (M.C. Gonzalez), ryoji@med.teikyo-u.ac.jp (R. Fukushima), pveera@kku.ac.th (V. Pisprasert), rb@sun.ac.za (R. Blaauw), dianacardenasbraz@gmail.com (D.C. Braz), fcarrasc@gmail.com (F. Carrasco), alfonsojose.cruz@salud.madrid.org (A.J. Cruz Jentoft), cuerda.cristina@gmail.com (C. Cuerda), davidevansmd@gmail.com (D.C. Evans), dravanessafuchs@gmail.com (V. Fuchs-Tarlovsky), lg3@ualberta.ca (L. Gramlich), shihp@ccmu.edu.cn (H.P. Shi), jeanette.hasse@BSWHealth.org (J.M. Hasse), michael.hiesmayr@gmail.com (M. Hiesmayr), nhiki@med.kitasato-u.ac.jp (N. Hiki), hajager@pl.hanze.nl (H. Jager-Wittenaar), moshuds@hotmail.com (S. Jahit), drajaqueznc@gmail.com (A. Jáquez), hkeller@uwaterloo.ca (H. Keller), st.klek@gmail.com (S. Klek), ainsley@nutritioncare.org (A. Malone), kmogensen@bwh.harvard.edu (K.M. Mogensen), nmori@aichi-med-u.ac.jp (N. Mori), mundi.manpreet@mayo.edu (M. Mundi), maurizio.muscaritoli@uniroma1.it (M. Muscaritoli), dorishuilan@yahoo.co.uk (D. Ng), ibolya.nyulasi@monash.edu (I. Nyulasi), matthias.pirlich@googlemail.com (M. Pirlich), stephane.schneider@univ-cotedazur.fr (S. Schneider), devanderSchueren@han.nl (M. Schueren), soranit09@gmail.com (S. Siltharm), pierre.singer@gmail.com (P. Singer), asteiber@eatright.org (A. Steiber), Tappenden@health.utah.edu (K.A. Tappenden), yu-jch@163.com (J. Yu), andre.vangossum@hubruxelles.be (A. van Gossum), cy614112@ms14.hinet.net (J.-Y. Wang), mwinkler@lifespan.org (M.F. Winkler), barazzoni@units.it (R. Barazzoni), compherc@upenn.edu (C. Compher).

¹ contributed equally.

^x Surgical Oncology Clinic, The Maria Skłodowska-Curie National Cancer Institute, Krakow, Poland^y The American Society for Parenteral and Enteral Nutrition, Silver Spring, MD, USA^z Department of Nutrition, Brigham and Women's Hospital, Boston, MA, USA^{aa} Department of Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan^{ab} Division of Endocrine, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN, USA^{ac} Department of Translational and Precision Medicine, Sapienza University of Rome, Italy^{ad} Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore^{ae} Department of Food, Nutrition and Dietetics, Latrobe University, Melbourne, Australia^{af} The School of Translational Medicine, Monash University, Melbourne, Australia^{ag} Imperial Oak Outpatient Clinic, Endocrinology, Gastroenterology and Clinical Nutrition, Berlin, Germany^{ah} Gastroenterology and Nutrition Department, Nice University Hospital, Côte d'Azur University, Nice, France^{ai} Department of Nutrition, Dietetics and Lifestyle, HAN University of Applied Sciences, Nijmegen, the Netherlands^{aj} Division of Human Nutrition and Health, Wageningen University&Research, Wageningen, the Netherlands^{ak} Ministry of Science and Technology, Bangkok, Thailand^{al} Institute for Nutrition Research, Rabin Medical Center, Petah Tikva, Intensive Care Unit, Herzlia Medical Center, Reichman University, Israel^{am} Mission, Impact and Strategy Team, Academy of Nutrition and Dietetics, Chicago, IL, USA^{an} Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USA^{ao} Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 100730, China^{ap} Department of Gastroenterology and Clinical Nutrition, Hospital Universitaire de Bruxelles (HUB), Free University of Brussels, Brussels, Belgium^{aq} Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital and Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan^{ar} Alpert Medical School of Brown University, Rhode Island Hospital, Surgical Nutrition Service, Providence, RI, USA^{as} Department of Medical, Technological and Translational Sciences, University of Trieste, Ospedale di Cattinara, Trieste, Italy^{at} Biobehavioral Health Science Department and Nutrition Programs, University of Pennsylvania School of Nursing, Philadelphia, PA, USA

ARTICLE INFO

Article history:

Received 16 March 2025

Accepted 17 March 2025

Keywords:

Malnutrition

Screening

Assessment

Muscle

Inflammation

SUMMARY

Background: The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 comprised of screening followed by assessment of three phenotypic criteria: weight loss, low BMI, and low muscle mass, and two etiologic criteria: reduced food intake/assimilation, and inflammation/disease burden. This planned update reconsiders the GLIM framework based on published knowledge and experience over the past five years.

Methods: A GLIM working group (n = 43 members) conducted a literature search spanning 2019–2024 using the keywords “Global Leadership Initiative on Malnutrition or GLIM”. Prior GLIM activities providing guidance for use of the criteria on muscle mass and inflammation were reviewed. Successive rounds of review and revision were used to achieve consensus.

Results: More than 400 scientific reports are published in peer-reviewed journals, forming the basis of 10 systematic reviews, some including meta-analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgement may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. Following two rounds of review and revision, the working group secured 100 % agreement with the conclusions reported in the 5-year update.

Conclusion: Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.

© 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In 2016, the Global Leadership Initiative on Malnutrition (GLIM) was founded. GLIM builds on efforts to address the priority for the development of a consensus approach for diagnosis of malnutrition [1] and to consolidate consensus around nutritional concepts and terminology [2]. The lack of consensus has hindered the development of a common nutrition language to support sharing of meaningful prevalence data, the testing of targeted interventions, and the monitoring of outcomes across the globe. Breakthroughs in our understanding of malnutrition in settings of disease/inflammation have supported a changing paradigm in how we fundamentally characterize malnutrition in clinical settings. These insights culminated in the 2019 GLIM consensus papers that provided a framework for a globally accepted diagnostic process that should be valid for adults in most settings, irrespective of methodological availability and resources [3–5].

Four major clinical nutrition societies, the American Society for Parenteral and Enteral Nutrition (ASPEN), the European Society for Clinical Nutrition and Metabolism (ESPEN), Federación Latinoamericana de Terapia Nutricional, Nutrición Clínica Y Metabolismo (FELANPE), and the Parenteral and Enteral Nutrition Society of Asia (PENSA), convened in 2016 to establish a core leadership committee, comprised of two representatives of each society and an expert working group comprised of 24 physicians and dietitians.

A modified Delphi process was used, which included several ballots, bi-annual meetings during the ASPEN and ESPEN congresses, and e-mail communications. After three years, consensus was reached, and the GLIM diagnostic model was published in three nutrition-related journals [3–5].

The consensus process arrived at a 2-step GLIM procedure that starts with nutrition screening followed by diagnostic assessment for confirmation of malnutrition. In subjects identified as at risk of malnutrition, all five GLIM criteria should be assessed to confirm the

presence of malnutrition. Three phenotypic and two etiologic criteria were selected from existing widely accepted approaches to diagnosis. All chosen criteria are well-established nutrition-related variables that, in their own capacity, have well-validated prognostic value for negative clinical outcomes, e.g., mortality. The three phenotypic criteria are non-volitional weight loss, low body mass index (BMI), and low muscle mass, whereas the two etiologic criteria are reduced food intake/food assimilation and disease burden/inflammation. To confirm a malnutrition diagnosis, at least one phenotypic and one etiologic criterion must be present. Still, in occasional cases, it will not be possible to assess all five criteria. When assessment of one or more criteria is not possible for compelling practical reasons, the diagnosis of malnutrition will still be possible if, among those available, one phenotypic and one etiologic criterion are fulfilled. For exclusion of the diagnosis, all five criteria need to be assessed. Further, the severity grading of malnutrition is based solely on the phenotypic criteria. When the criteria assessment confirms the diagnosis of malnutrition, the subject should undergo a comprehensive nutritional assessment, according to available resources, in order to establish a treatment plan. However, it should be noted that the GLIM consortium advises against using hypoalbuminemia as an indicator of malnutrition due to its limited sensitivity and specificity when used for this purpose [6].

The new approach to malnutrition diagnosis uses similar variables to other validated tools to provide an opportunity to standardize language about the condition. The intention is also to offer a simplified version for use by clinicians with less nutrition expertise and to serve settings with limited staffing and measurement resources. The GLIM approach was primarily not intended to supplant other diagnostic methods in use by nutrition experts, but rather to integrate the shared variables when possible.

The original consensus document stated, “the GLIM consensus should be re-evaluated based upon review of new studies and advances in screening and assessment every 3–5 years”. The aim of this paper is to report the current consensus of the GLIM consortium and to share discussions on possible revisions and amendments.

2. Methods - the consensus procedure

The GLIM Core Committee, i.e., two representatives from ASPEN (GJ, CC), ESPEN (TC, RB), FELANPE (MITDC, MCG), and PENZA (RF,

VP), respectively, supervised the overall process. A GLIM Working Group (n = 43 participants) with broad global and professional representation was instituted based on the suggestions from the GLIM Core Committee. A literature search was conducted using the keywords “Global Leadership Initiative on Malnutrition or GLIM” between 2019 and 2024. Ten systematic reviews and meta-analyses of GLIM validation studies conducted from 2022 to 2023 were summarized and evaluated. Results from ongoing working group activities on implementation and integration, guidance for the GLIM criteria on muscle mass and inflammation, as well as recently started review activities, e.g., procedures for malnutrition risk screening and food intake/assimilation assessment are reported.

A first draft of the consensus document was provided by TC and GJ, in close consultation with the GLIM Core Committee. This draft was then circulated among participants of the working group, and the text went through two rounds of revision until a consensus was reached at a threshold level of at least 75 % agreement.

3. Validation studies between 2019 and 2024 and GLIM bibliometric after five years

Since the phenotypic and etiologic criteria were selected from widely accepted diagnostic models introduced over the past fifty years, the GLIM consortium decided in 2019 to recommend immediate implementation while promoting ongoing validation studies. To support the performance of sound validation studies, the GLIM consortium provided a guidance paper [7,8] on how to perform studies targeting construct or criterion validity, i.e., to assure that the model identifies malnutrition and predictive validity, i.e., that the model identifies cases with adverse clinical outcomes.

A literature search of PubMed used “Global Leadership Initiative on Malnutrition or GLIM” as the search term for the period of 2019 to May 2024. The search identified more than 400 validity and feasibility studies, not taking reviews or commentaries into account. These publications provide evidence that GLIM has good concurrent criterion validity when compared to established models, e.g., Subjective Global Assessment (SGA) [9], Mini Nutritional Assessment-Short Form (MNA-SF) [10], and the Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition Indicators to Diagnose Malnutrition (AAIM) [11].

Table 1
Summary of Systematic Reviews, some including Meta-Analyses, Evaluating the Global Leadership Initiative on Malnutrition (2019–2024) Criterion or Predictive Validity. Search is through March 5, 2024. Please see long version of Table 1 in the supplemental materials for additional study details.

Author, Year	Purpose	Sample Size
Huo, 2022 [12]	Assess criterion validity of GLIM criteria for diagnosing malnutrition	20 studies with 10,781 patients
Diaz, 2023 [13]	Assess criterion validity of GLIM criteria in patients admitted to the intensive care unit	5 studies with 337 patients
Bian, 2023 [13]	Prevalence of malnutrition by GLIM criteria with and without a screening step; Assess risk of mortality with malnutrition	64 studies with 47,654 patients
Brown, 2023 [16]	Assess risk of survival and disease-free survival in adults with cancer and malnutrition	21 studies with 28,726 patients
Sanchez-rodriguez 2023 [15]	Assess risk of all-cause mortality in older adults with malnutrition; describe how muscle mass was assessed.	17 studies (15 cohort, 2 cross-sectional) with data from 10,671 hospitalized patients, 485 nursing home patients, and 8096 community-dwelling
Yin, 2023 [17]	Assess risk of overall survival in patients with cancer and malnutrition	9 studies with 8829 patients
Lidoriki, 2022 [18]	Assess risk of postoperative complications and survival in patients with gastrointestinal cancer surgery and malnutrition	7 studies with data from 3662 patients
Matsui, 2022 [19]	Assess the risk of mortality and complications in patients with cancer and malnutrition	10 studies with 11,700 patients
Peng, 2022 [20]	Assess the risk of mortality and complications in patients with cancer and malnutrition	15 studies with data from 14,573 patients
Xu, 2022 [21]	Assess the risk of mortality and complications in patients with cancer and malnutrition	12 studies with 6799 patients

Likewise, predictive validity is comparable to other malnutrition diagnostic instruments.

During the same period (2019–May 2024), the three original GLIM consensus papers have been cited >5000 times (Google Scholar), >2300 times in Scopus, and >3000 times in Web of Science.

3.1. Systematic reviews and meta-analyses of validation studies

The large number of individual validation studies has provided the basis for ten systematic reviews (SR), some including meta-analyses, exploring different aspects and settings of GLIM (Table 1) published through May 2024 [12–21]. We elected to focus on the SRs and meta-analyses rather than attempt analyses of the multiple individual studies. The SRs are based on major validation studies and include studies from diverse regions of the world. Eight focus on predictive validity and encompass approximately 100 studies with >100,000 patients.

Criterion validity: Two meta-analyses focus on criterion validity [12,13]. One included a general sample (mixed settings) of 20 studies with 10,781 patients from 13 countries, showing a sensitivity of 72 % with range 51 %–92 % (i.e., capacity to identify true positive cases) and specificity of 82 % with range of 73–98 % (i.e., capacity to identify true negative cases) relative to Subjective Global Assessment (SGA) or Patient Generated SGA (PG-SGA) as the mainly used semi-gold standard [7,8]. With an AUC of 0.82, the authors stated that GLIM has good diagnostic accuracy. Malnutrition prevalence was 44 % in the total sample [12]. A smaller meta-analysis that included five ICU studies concluded that the small sample of 337 patients and the heterogeneity limited the resulting sensitivity 65.5 % (95 % CI: 35 %–86.8 %). Specificity was 86.9 % (95 % CI: 59.3 %–96.9 % [13].

Predictive validity: Concurrently, eight SRs, some with meta-analyses, of predictive validity (mainly mortality as the outcome) were published [14–21] (Table 1). The largest meta-analysis was performed in general hospitalized patients, with 47,654 participants [14]. Among the 64 articles, 34 were from Asia, 20 from Europe, nine from the Americas, and one from Oceania. Many diagnoses were included, e.g., cancer, COVID-19, renal failure requiring hemodialysis, inflammatory bowel disease, and cerebrovascular accident [14]. Increased one-year mortality in patients diagnosed with malnutrition by the GLIM approach was indicated by HR 2.62 (95 % CI: 1.95–3.52). Heterogeneity was managed by random effects models. The corresponding HR for “beyond 1-y mortality” was 2.04 (95 % CI: 1.70–2.45). Malnutrition prevalence was 40–50 % on average [14].

The SRs included studies conducted in hospital settings [14], among community-dwelling older adults [15], and in nursing homes [15]. Malnourished patients diagnosed by the GLIM approach had a consistent increase in mortality. Among hospitalized patients with malnutrition, there was a 1.2–7.2-fold increase in mortality over four months; among nursing home patients with malnutrition, there was a 1.3–4.7-fold increase in mortality over 1 or 2 years, and finally, among patients in community settings with malnutrition there was a 1.6–4.4-fold increase in mortality over 2–14 years [15].

The largest SR/meta-analysis focused on patients with cancer included 21 cohort studies with 28,726 patients (14 from China, two from Spain, two from Australia, one from Greece, one from Turkey, and one from Japan) [16]. Many types of cancer were included. Mortality and disease-free survival were consistently worse among those diagnosed with malnutrition by the GLIM approach, and these clinical outcomes were even worse for those patients with severe compared to moderate malnutrition.

A limitation of these reviews is that some of the same studies are included in multiple reviews. Three reviews did not include information on whether all of five GLIM criteria were addressed by every included study. Overall, approximately 80 % of the included individual studies reported an assessment of muscle mass.

4. Efforts to facilitate the implementation and integration of GLIM

To better understand how the GLIM consensus has been implemented since its introduction, the GLIM Implementation, Dissemination, and Integration Working Group conducted a global survey in early 2023 to evaluate the implementation of the GLIM approach, including barriers and enablers to implementation in both practice and research. General results from over 1500 respondents indicated the GLIM consensus had either been implemented (25 %) or its implementation was in process (20 %) [22,23]. Of those who had implemented GLIM or were in progress, 63 % reported to be in hospital settings, 19 % in private practice or primary care, and 5 % in long term care (total of 100 % included “other” workplace settings; n = 574 respondents). Respondents indicating GLIM implementation or progress were from the following continents: Europe (40 %), North America (24 %); South America (21 %), Africa (7 %), Asia (6 %) and Oceania (2 %); (n = 631 respondents). These results were surprising as the adoption and implementation of new practices have generally been shown to take from 17 to 20 years [24]. The next steps will include seeking publication of survey findings and using these results to provide practical tips for implementing GLIM and overcoming barriers. An opinion paper has been published describing the rationale for implementing the GLIM framework in clinical dietetic practice [25]. Dissemination of GLIM activities has been ongoing, with dedicated educational sessions held at several nutrition society conferences. These sessions have provided updates for attendees, including “guidance for muscle mass assessment”, “inflammation position statements”, GLIM survey data, and methods to integrate the GLIM consensus with other malnutrition diagnostic approaches. Examples of successful integration with the AAIM approach were presented at the recent ASPEN 2024 Nutrition Science and Practice Conference in Tampa, FL [26]. The participating GLIM societies have also included invited presentations of national or regional GLIM experiences at their annual meetings.

A significant advancement in GLIM implementation is the endorsement of the GLIM consensus for reimbursement by the Ministry of Health, Labor and Welfare of Japan [27], as well as the acknowledgment of the GLIM criteria for the diagnosis of disease-related malnutrition (DRM) by the World Health Organization (WHO) Regional Office for Europe in its manual on brief interventions for non-communicable disease risk factors in primary care [28]. WHO Europe has also published, in collaboration with ESPEN, two fact sheets on disease-related malnutrition [29] and tuberculosis [30], both quoting the GLIM criteria as a suggested malnutrition diagnostic tool.

5. Re-evaluation process

A final round of revision resulted in 100 % of the working group supporting the conclusions of the update. Figure 1 summarizes the updates performed after the re-evaluation process. Figure 1 is adapted from the original GLIM consensus papers [3–5]. In this update, each step and suggested amendments are discussed based on new experience and knowledge accrued over the past five years.




Fig. 1. GLIM diagnostic scheme for screening, diagnostic assessment and grading of malnutrition. First, identify subjects with risk factors for malnutrition. Second, apply the two etiologic criteria and the three phenotypic criteria. When at least one of each set of criteria is fulfilled, the diagnosis of malnutrition is confirmed. Third, determine severity, i.e., moderate or severe malnutrition based on the degree of aberration in the phenotypic criteria. This figure is adapted from the original 2019 consensus paper [3–5].

6. Is there a need to clarify the malnutrition screening procedure after the introduction of GLIM?

The international clinical nutrition community has, until recently, focused on the introduction of procedures for nutritional screening into regular clinical practice in hospitals, outpatient care, primary care, and other care settings. This is intended to identify individuals at a higher risk for malnutrition who require nutritional assessment and intervention. Many validated screening tools are now available [31,32], with the majority focusing on the identification of individuals who already have signs of malnutrition, while others identify risk factors for developing malnutrition [33–36]. Tools focusing on identifying existing malnutrition mostly use similar sets of variables, e.g., weight loss, low BMI, disease burden, but these variables are combined in various manners and applied with different cutoff values.

The experience collected after the introduction of the GLIM procedure indicates that the screening tool selected, i.e., tools that identify “risk of malnutrition” vs. tools that identify “malnutrition”, affects the prevalence of malnutrition diagnosed by GLIM [37,38]. In addition, conservative screening methods with limited specificity might result in false negative diagnosis outcomes.

Global consensus to define the “risk of malnutrition” is not established. For this reason, a new GLIM working group initiative is ongoing with the aim to provide clarity on how, when and if screening should be used within the GLIM approach [31,32]. Results from this initiative are expected in early 2025. In the meantime, the GLIM consortium continues to recommend using existing screening procedures.

7. What have we learned about the feasibility of the phenotypic criteria?

Non-volitional weight loss: In general terms, weight loss is perhaps the most widely accepted variable for nutritional assessment. In the GLIM original paper, the decisions on cutoffs for weight loss were based on a consensus process accounting for recommendations from the major established screening and

diagnostic instruments. The cutoff recommendations, considering both acute and chronic weight loss, were >5 % weight loss within the past six months or >10 % weight loss beyond six months.

There appears to be no indication to change this recommendation at this time.

Low BMI: The utility of body mass index (BMI) as an indicator of malnutrition has been questioned in regions of the globe where obesity is common. However, low BMI/underweight is a common global indicator of malnutrition associated with unfavorable outcomes. This is especially true for those with chronic starvation or advanced chronic illness and among some older adults. Thus, it is important to obtain BMI for all individuals, irrespective of their size. Determination of BMI is an established and easily performed practice for most clinical encounters. Additionally, obtaining BMI, concurrent with weight loss history, will help to promote understanding among practitioners that even among those who are overweight or obese, malnutrition is increasingly prevalent [39]. Furthermore, determination of BMI is advocated to identify overweight and obesity because of their associations with increased risk of co-morbidities such as diabetes mellitus and heart disease. Such individuals may be evaluated readily for malnutrition by meeting the GLIM phenotypic criterion for non-volitional weight loss or when appropriate expertise and resources are available by determination of low muscle mass (see text below on the low muscle mass criterion). For patients with fluid overload (e.g. in non-compensated heart, renal, and liver failure), BMI and weight loss may be difficult criteria to apply for malnutrition diagnosis. However, weight loss history may be obtained verbally from the patient or surrogate or from medical records.

The suggested BMI cutoffs are <20 kg/m² and <22 kg/m² in people <70 and ≥ 70 years, respectively. For people of Asian origin, the corresponding recommended cutoffs for <70 and ≥ 70 years are 18.5 kg/m² and 20 kg/m², respectively. Consideration of specific BMI cut points and their application across the globe is subject to continued investigation and discussion.

There appears to be no compelling information to warrant a change of the low BMI criterion at this time.

Low muscle mass: The skeletal muscles constitute the largest organ of the body and provide the major prerequisites for protein regulation, physical function, and activities of daily living. Muscle size and function are deeply dependent on an adequate and sufficient nutrient intake, including protein and energy, and loss of muscle mass is a devastating component of malnutrition. This loss may be especially profound in the malnourished patient with significant inflammation, as muscle catabolism is usually elevated in cases of severe illness or injury.

The original GLIM consensus did not provide detailed information on how to measure muscle mass or how to define low muscle mass. For this reason, a GLIM working group later published such guidance [40,41]. Since the availability of specific methods and the feasibility of implementing them in clinical practice are highly prioritized by the GLIM framework, a range of methods was recommended. The choice of method should be based on the availability of expertise, resources, and valid applicable cutoffs for the intended population. Magnetic resonance imaging (MRI) can be considered a gold-standard method for accuracy [42], but MRI is not routinely available for the assessment of muscle mass [40–42]. Thus, the working group recommended for GLIM implementation the use of dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), computerized tomography (CT), or ultrasound (US). CT evaluation of muscle mass can be an opportunity when the examination is performed for other indications, such as abdominal CT scans for oncologic or gastrointestinal disease purposes. In the absence of knowledge and availability of advanced technical devices, then acceptable methods for GLIM

implementation also include calf or arm anthropometry and subjective muscle mass assessment by trained health professionals conducting nutrition-focused physical examinations. However, irrespective of the method used, markedly elevated BMI and fluid accumulation may confound accurate assessment of muscle mass.

The guidance papers clarified that low muscle strength [40,41], although often closely associated with loss of muscle mass and included in full nutritional assessment following malnutrition diagnosis, is not a component of the GLIM diagnostic algorithm. For this reason, it should not be used as a surrogate for muscle mass assessment [43]. Still, muscle strength testing, e.g. hand dynamometry, is vital if sarcopenia is a diagnostic consideration.

Most body composition assessment tools have limitations in their application to adults living with obesity and may need specific adjustments for muscle mass assessment. Calf circumference with BMI adjustments has been proposed for use in clinical practice and could represent an appealing approach once additional validation is available [44]. DXA and BIA with population-specific equations are also options for muscle mass assessment in subjects with obesity that is not severe [45]. A recent consensus initiative on sarcopenic obesity proposed to normalize muscle mass for total body weight [46]. Validation of this approach to diagnose sarcopenic obesity and its relevant clinical outcomes is underway, and it could represent a potential future refinement for muscle mass assessment in persons with obesity and malnutrition.

Preliminary recommendations on cutoffs for muscle mass, using various methods, are provided in Table 2. Cutoffs should be sex-, ethnic-, and device-specific. As different approaches can be used to establish cutoffs for low muscle mass definition, concurrent global consensus initiatives on sarcopenia and sarcopenic obesity are underway [46,47]. The GLIM consortium has appointed a working group to consider this criterion and its cutoffs, including a systematic review and modified Delphi procedure. The GLIM network also considers it of strategic importance to promote agreement and consensus between the relevant global initiatives.

8. What have we learned about the feasibility of the etiologic criteria?

Reduced food intake/assimilation: There are numerous causes for reduced food intake and assimilation. Food insecurity under low-income circumstances or famine during war and natural

catastrophes is still afflicting millions of people across the globe. A variety of disease conditions and medications often cause appetite loss. “Anorexia of aging” may explain the loss of appetite experienced by some persons of advanced age that do not appear to have known disease conditions that impact upon appetite and are not receiving known appetite suppressing treatments. Such individuals appear to have low-grade inflammation and associated hunger-satiety imbalance [48]. Psychiatric conditions, such as depression and anorexia nervosa, are also associated with reduced food intake. Chewing and swallowing problems occur in older ages and in some disease conditions, e.g., neurological diseases and various dementia disorders. Gastrointestinal disturbances such as inflammatory bowel disorders, malabsorptive disorders, or post-surgical short bowel may also contribute to impaired assimilation of nutrients. A list of conditions was provided in the original guidance [3–5] that could be used to determine assimilation challenges. However, severity and duration were not considered at that time. The original GLIM paper stated, in accordance with current practice, that this GLIM criterion is fulfilled by a food intake <50 % of calculated energy requirement for >1 week, any reduction in food intake for >2 weeks, or any chronic gastrointestinal condition that adversely affects food assimilation or absorption.

As there is no standardized approach for assessment or interpretation of inadequate intake/assimilation, the GLIM consortium has appointed a working group to consider this criterion. The process includes a scoping review and a modified Delphi procedure. Until this process is completed, there is no indication to change the current recommendation.

Inflammation/disease burden: There is a strong consensus that many diseases or conditions are of inflammatory origin and/or elicit inflammatory responses. Malnutrition may result from inflammation-driven catabolic muscle loss, anorexia, altered metabolism, and associated micronutrient deficiencies. However, the original GLIM consensus papers did not provide detailed guidance as to how to assess inflammation in support of malnutrition diagnosis.

A GLIM Working Group, therefore, undertook a robust modified Delphi process to provide comprehensive guidance [49,50]. Seven statements were developed (Table 3) that conclude that the occurrence of acute or chronic disease, infection, or injury that is often/usually associated with inflammatory activity may fulfill the GLIM disease burden/inflammation criterion, and confirmation by

Table 2

Examples of recommended thresholds for low muscle mass or its surrogate markers. Adjustments should be made by height², weight or BMI (for use in persons with obesity). The recommendations are feasible for adults [40,41].

	Males	Females
Appendicular lean Mass index (ALMI), kg/m ^{2a,b} [53,54] (DXA)	<7	<5.5
Appendicular skeletal muscle Mass index (ASMI) or (ALMI) ^a kg/m ^{2c} [55]		
Bioelectrical impedance analysis (BIA) ^c [56]	<7	<5.7
Dual energy X-ray absorptiometry (DXA) ^c [57]	<7	<5.4
Fat-free Mass index (FFMI), kg/m ² [58,59] (BIA)	<17	<15
Appendicular lean Mass (ALM)/weight (%) ^d [60] (DXA)	<25.7	<19.4
ALM ^d /Body Mass index (BMI), m ² [61] (DXA)	<0.827	<0.518
Calf circumference, cm ^{e,f} [44]	<33	<32

^a Appendicular Lean Mass index should alternatively (and more correct) be called Appendicular Lean Soft Tissue index (ALSTI), kg/m² [52].

^b Recommendation from The European Working Group on Sarcopenia in Older People 2 (for Caucasians) [53].

^c Recommendation from The Asian Working Group for Sarcopenia (for Asian populations) [55].

^d Appendicular Lean Mass (ALM)/weight (%) should alternatively (and more correct) be called Appendicular Lean Soft Tissue (ALST)/weight (%) [52].

^e The recommended cutoffs of <33 cm and <32 cm in males and females, respectively, were in the original GLIM paper based on consensus within the GLIM working group. The cutoffs refer to the NHANES data [44], and correspond to the figures in-between –1 SD and –2 SD; i.e. 32 cm and 34 cm (males) and 31 cm and 33 cm (females). Cutoffs for muscle mass are currently under discussion within a GLIM working group and within the scientific community. The cutoffs will likely be updated in the near future. For this reason the GLIM CC cutoffs are not changed at this time.

^f In adults with obesity, decrease the measured value by 3 cm (BMI 25–30) or 7 cm (BMI 30–40) [44].

Table 3

Guidance statements for assessment of the GLIM etiologic criterion of inflammation [49,50].

Statement 1: Fulfilment of the GLIM inflammation criterion	The occurrence of acute or chronic disease, infection, or injury that is often/usually associated with inflammatory activity may fulfill the GLIM disease burden/inflammation criterion; i.e., confirmation by laboratory markers is not always necessary. When testing is available, we recommend that laboratory markers be measured in uncertain cases to help confirm the inflammatory character of the underlying disease or condition.
Statement 2: Conditions with severe/moderate acute inflammation	Confirmation of the presence of severe or moderate acute inflammation should be guided by clinical judgement based upon underlying diagnosis or condition, clinical signs, or laboratory markers. Examples of acute diseases or conditions that may be associated with acute inflammation of severe/moderate degree include critical illness or sepsis, and exacerbations of COPD or Crohn's disease.
Statement 3: Conditions with mild to moderate chronic inflammation	Confirmation of the presence of mild to moderate chronic inflammation should be guided by clinical judgement based upon underlying diagnosis or condition, clinical signs, or laboratory markers. Examples of diseases that may be associated with chronic inflammation of mild/moderate degree include congestive heart failure, cancer, and chronic kidney disease.
Statement 4: Conditions with no clear or perceptible inflammation	Disease conditions that have no clear or perceptible inflammatory components will not fulfill the disease burden/inflammation criterion unless confirmed by laboratory analyses. Examples include anorexia nervosa, depression, and dysphagia, and non-disease conditions that are associated with limited resources or environment that compromise food security, access, or intake, including poverty, famine, and war.
Statement 5: Laboratory markers indicating inflammation	The documentation of laboratory markers indicating inflammation may support confirmation of the inflammation criterion. Use of CRP is recommended in cases of clinical uncertainty.
Statement 6: Application of CRP testing	For acute conditions, CRP levels ≥ 10 times higher than the upper reference value for the methodology of the selected clinical laboratory can be used to support the presence of moderate to severe acute inflammation. For chronic conditions, serial measures of CRP higher than the upper reference value for the methodology of the selected clinical laboratory support the presence of the chronic inflammation criterion.
Statement 7: Application of clinical judgement	Clinical judgement based upon integration of underlying diagnosis or condition, clinical signs, and/or laboratory markers should guide confirmation of the presence of inflammatory disease or condition. The sound interpretation of some of these indicators requires clinical training and expertise.

COPD=Chronic Obstructive Pulmonary Disease, CRP=C-reactive Protein.

laboratory markers is not always necessary. Examples of acute and chronic conditions are provided. In cases of uncertainty, confirmation by C-reactive protein (CRP) analysis is recommended. Serial measurements of CRP are recommended, and repeated measures higher than the upper cutoff level of the selected clinical laboratory support the presence of chronic inflammation. Application of clinical judgement is encouraged (Table 3).

9. Severity grading

The original consensus paper recommended severity grading (moderate or severe malnutrition) based on any of the three phenotypic criteria. Unfortunately, it is not currently possible to broadly attempt a distinction between moderate and severe reductions of muscle mass because only some of the current methodological approaches allow for this level of differentiation. Further research is needed to inform severity grading in muscle mass assessment.

The GLIM consortium does not currently identify a rationale to warrant changes in the recommendations for severity grading for any of the phenotypic criteria (Table 4).

10. What have we learned about GLIM integration with other nutrition diagnostic tools?

The implementation survey [22,23] identified that having another malnutrition diagnostic approach in place that was fully

endorsed at the institutional or regional level was a barrier to the use of GLIM. However, the GLIM consensus approach was mainly intended to provide a feasible alternative for clinicians in clinical sites with more limited nutrition knowledge and resources rather than to displace other valid methods used by nutrition experts. The GLIM approach endorses core phenotypic and etiologic criteria that are already in widespread use throughout the world. GLIM promotes the global use of these criteria that may, in turn, be readily used with other approaches.

Some centers have harmonized the GLIM approach with pre-existing methods, such as the Academy ASPEN Indicators of Malnutrition (AAIM) and Subjective Global Assessment (SGA). Since GLIM, AAIM, and SGA use similar variables, having staff members gather data using these established AAIM or SGA frameworks enables a crosswalk to the GLIM structure. Depending upon the degree of regional investment in pre-existing validated approaches to malnutrition diagnosis like AAIM or SGA, either adoption of GLIM or integration with GLIM may be considered.

11. Conclusions and perspectives

1. The GLIM approach has found a positive reception within the global clinical nutrition community, i.e., GLIM appears to have the potential to become widely adopted as a practical framework for the diagnosis of malnutrition in diverse clinical settings with widely variable resource availability.

Table 4

Thresholds for severity grading of malnutrition into Stage 1 (Moderate) and Stage 2 (Severe) malnutrition [3–5].

	Phenotypic Criteria ^a		
	Weight loss (%)	Low body mass index (BMI), (kg/m ²) ^b	Low muscle mass
Stage 1/Moderate malnutrition (requires 1 phenotypic criterion that meets this grade)	5–10 % within the past 6 mo, or 10–20 % beyond 6 mo	<20 if < 70 yr, <22 if $\geq$ 70 yr	Data for severity grading are not available
Stage 2/Severe malnutrition (requires 1 phenotypic criterion that meets this grade)	>10 % within the past 6 mo, or >20 % beyond 6 mo	<18.5 if < 70 yr, <20 if $\geq$ 70 yr	Data for severity grading are not available

^a Severity grading is based upon the noted phenotypic criteria.

^b Further research is needed to secure consensus reference BMI data for Asian populations in clinical settings.

2. The growing number of validation and feasibility studies have formed the basis for systematic reviews and meta-analyses on criterion and predictive validity. The results indicate that GLIM has undergone extensive validation and has a well-established evidence base. Variations in prevalence, sensitivity and specificity between studies may possibly relate to the fact that some of the studies did not use all five GLIM criteria or that the populations evaluated vary. To exclude the diagnosis of malnutrition, all five criteria need to be measured. Making it a practice point to assess all five GLIM criteria in prospective studies may help to resolve the discrepancies in research to date. Statistical modeling based on large available databases may allow for estimation of the individual weights of the GLIM criteria, and reassessment of the actual cut-off value. Furthermore, application of the formal methods used for the development of scoring systems may allow for increased precision of the GLIM approach and integration of the interactions between risk indicators.
3. Another key observation since the 2-step GLIM procedure was launched, is that the choice of malnutrition risk screening tool results in variations in malnutrition prevalence. A GLIM working group is currently performing two modified Delphi studies to provide further guidance for screening within the GLIM framework.
4. In the original consensus publication, there remained uncertainties as how to assess the phenotypic criterion on low muscle mass and the etiologic criterion on inflammation/high disease burden. Two GLIM Working Groups have since provided more detailed guidance, e.g., calf circumference may be considered in the absence of machine-based techniques to evaluate muscle mass [40,41], and clinical judgement of inflammatory disease burden may only require laboratory confirmation (by C-reactive protein) in cases of uncertainty [49,50]. For the phenotypic criteria of non-volitional weight loss and low BMI, no new data justify any changes from the original recommendations.
5. Malnutrition is a common occurrence among individuals living with obesity, especially in the form of deficiencies of proteins, essential nutrients, and micronutrients. The assessment of muscle mass in the setting of obesity is particularly challenging. Parallel initiatives within the scientific community are seeking to address this issue [46]. The GLIM consortium is an active participant in these efforts. Testing the validity of the GLIM approach to identify malnutrition in subjects with obesity is a further challenge that will be addressed.
6. Other ongoing GLIM working group initiatives include the evaluation of the etiologic food intake and assimilation criterion, as well as how to adapt the GLIM framework for use in the intensive care setting, and guidance on cutoffs for low muscle mass.
7. In 2019, the GLIM consortium foresaw securing endorsements from leading nutrition professional societies and set priorities to promote dissemination, validation testing, and feedback. More recently, a discussion has been opened with the International Classification of Diseases (ICD) group at WHO in Geneva with the aim of modernizing the ICD codes for malnutrition through the use of common key variables that are shared across the leading approaches to malnutrition diagnosis [51]. Since the current ICD-11 edition does not have a code for malnutrition/undernutrition in adults, this revision is a high priority because the ICD scheme guides clinical diagnosis and reimbursement across much of the world.
8. The current phenotypic and etiologic criteria for the diagnosis of malnutrition are summarized in Table 5.
9. The GLIM consensus should continue to be re-evaluated based upon review of new studies and advances in the field at least every five years.

GLIM Core Leadership Committee

Representing American Society for Parenteral and Enteral Nutrition (ASPEN): Gordon L. Jensen, Charlene Compher. Representing European Society for Clinical Nutrition and Metabolism (ESPEN): Tommy Cederholm, Rocco Barazzoni. Representing Federación Latinoamericana de Terapia Nutricional, Nutrición Clínica Y Metabolismo (FELANPE): Maria Isabel T.D. Correia, M. Cristina

Table 5

Summary of the phenotypic and etiologic criteria for the diagnosis of malnutrition.

Phenotypic Criteria ^a			Etiologic Criteria ^a	
Weight loss (%)	Low body mass index (BMI), (kg/m ²)	Low muscle mass ^a	Reduced food intake or assimilation ^{b,c}	Inflammation ^{d,e,f}
>5 % within past 6 months, or >10 % beyond 6 months	<20 if < 70 years, or <22 if ≥ 70 years Asia: <18.5 if < 70 years, or <20 if ≥ 70 years	Determined by validated body composition measuring techniques ^a	≤50 % of ER > 1 week, or any reduction for >2 weeks, or any chronic GI condition that adversely impacts food assimilation or absorption ^{b,c}	Occurrence of acute ^d or chronic ^e disease, infection or injury that are often/usually associated with inflammatory activity ^f

This table is adapted from the 2019 consensus papers [3–5]. The table and the recommended cutoffs remain largely unchanged.

GI = gastro-intestinal, ER = energy requirements.

^a All five criteria should be assessed. At least one phenotypic criterion and one etiologic criterion are required for the diagnosis of malnutrition.

^a Bioelectrical impedance analysis (BIA), dual-energy absorptiometry (DXA), computerized tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US) are methods that can be used when experience and relevant reference values are available. When not available or by regional preference, physical examination or standard anthropometric measures such as calf circumference (CC) or mid-upper arm muscle circumference (MUAC) may be used. Thresholds for reduced muscle mass need to be adapted to race (Asia).

^b Consider gastrointestinal symptoms as supportive indicators that can impair food intake or absorption e.g. dysphagia, nausea, vomiting, diarrhea, constipation, or abdominal pain.

^c Reduced assimilation of food/nutrients is associated with malabsorptive disorders such as short bowel syndrome, pancreatic insufficiency, and after bariatric surgery. It is also associated with disorders such as esophageal strictures, gastroparesis, and intestinal pseudo-obstruction.

^d Acute disease and injury-related severe inflammation is likely to be associated with major infection, burns, trauma, or closed head injury. Other acute disease/injury-related conditions are likely to be associated with mild to moderate inflammation.

^e Chronic disease-related inflammation is generally mild to moderate and often recurrent and is likely to be associated with malignant disease, chronic obstructive pulmonary disease, congestive heart failure, chronic renal disease, or any disease with chronic or recurrent inflammation. Note that transient inflammation of a mild degree does not meet the threshold for this etiologic criterion.

^f C-reactive protein may be used as a supportive laboratory measure.

Gonzalez Representing Parenteral and Enteral Nutrition Society of Asia (PENSA): Ryoji Fukushima, Veeradej Pisprasert.

Author contributions

All authors contributed to the conception of the project and to writing, review and editing. Gordon Jensen and Tommy Cederholm led the project from inception to completion. They as well as Charlene Compher and Rocco Barazzoni contributed data curation, formal analysis, writing of the original and subsequent drafts, methodology, investigation, supervision, project administration, and validation. All authors agree to be fully accountable for ensuring the integrity and accuracy of the work and all authors affirm that they have read and approved the final manuscript.

Ethical board approval

Not required for this type of consensus project.

Permission for use of previously published materials

Adapted figure and tables are from the prior Clinical Nutrition publication; 2019; 38:1–9.

Financial disclosure statement

None declared.

Conflict of interest

Tommy Cederholm disclosed receiving lecture honoraria from Fresenius-Kabi, Nutricia/Danone, and Nestle. M. Isabel T. D. Correia reported support from Abbott, Baxter, Danone, Fresenius, Nestlé for lectures and educational materials. David Evans disclosed support from Abbott Nutrition for consulting and speaking honoraria; Fresenius Kabi for consulting and speaking honoraria; and Alcresta Therapeutics for consulting and speaking honoraria. M. Cristina Gonzalez disclosed receiving honoraria and/or paid consultancy from Abbott Nutrition, Nutricia, and Nestle Health Science Brazil. Jeanette Hasse disclosed serving on the Speakers bureau for Alcresta Therapeutics. Ainsley Malone disclosed that she is an employee of ASPEN. Kris M. Mogensen disclosed serving as an Advisory Board Member for American Regent. Manpreet Mundi disclosed research grants from Nestle and Northsea as well as service on the advisory boards of Baxter, NutriShare, and Otsuka. Alison Steiber reported that she is an employee of the Academy of Nutrition and Dietetics and that she has received grant funding from the Academy of Nutrition and Dietetics Foundation and the Administration for Community Living.

All other authors reported no disclosures.

Acknowledgments

We acknowledge the support of our core nutrition societies and the core committee and working group.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.clnu.2025.03.018>.

References

- [1] Jensen GL, Mirtallo J, Compher C, Dhaliwal R, Forbes A, Grijalba RF, et al. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the international consensus guideline committee. *J Parenter Enteral Nutr* 2010;34:156–9.
- [2] Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Compher C, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. *Clin Nutr* 2017;36:49–64.
- [3] Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. *J Parenter Enteral Nutr* 2019;43:32–40.
- [4] Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. *Clin Nutr* 2019;38:1–9.
- [5] Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community. *J Cachexia Sarcopenia Muscle* 2019;10:207–17.
- [6] Evans DC, Corkins MR, Malone A, Miller S, Mogensen KM, Guenter P, et al. The use of visceral proteins as nutrition markers: an ASPEN position paper. *Nutr Clin Pract* 2021;36:22–8. Erratum in: *Nutr Clin Pract* 2021;36:909.
- [7] Keller H, de van der Schueren MAE; for the GLIM Consortium Global Leadership Initiative on Malnutrition (GLIM). Guidance on validation of the operational criteria for the diagnosis of protein-energy malnutrition in adults. *J Parenter Enteral Nutr* 2020;vol. 44:992–1003.
- [8] de van der Schueren MAE, Keller H; for the GLIM Consortium. Global leadership initiative on malnutrition (GLIM): guidance on validation of the operational criteria for the diagnosis of protein-energy malnutrition in adults. *Clin Nutr* 2020;39:2872–80.
- [9] Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment? *J Parenter Enteral Nutr* 1987;11: 8–13.
- [10] Guigoz Y, Vellas B. Nutritional assessment in older adults: MNA® 25 years of a screening tool and a reference standard for care and research; what next? *J Nutr Health Aging* 2021;25:528–83.
- [11] White JV, Guenter P, Jensen G, Malone A, Schofield M. Academy Malnutrition Work Group, A.S.P.E.N. Malnutrition Task Force; A.S.P.E.N. Board of Directors. Consensus statement: Academy of nutrition and dietetics and American society for parenteral and enteral nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *J Parenter Enteral Nutr* 2012;36:275–83.
- [12] Huo Z, Chong F, Yin L, Lu Z, Liu J, Xu H. Accuracy of the GLIM criteria for diagnosing malnutrition: a systematic review and meta-analysis. *Clin Nutr* 2022;41:1208–17.
- [13] Diaz G, T D, Correia MI, Gonzalez MC, Reyes M. The global leadership initiative on malnutrition criteria for the diagnosis of malnutrition inpatients admitted to the intensive care unit: a systematic review and meta-analysis. *Clin Nutr* 2023;42:182–9.
- [14] Bian W, Li Y, Wang Y, Chang L, Deng L, Li Y, et al. Prevalence of malnutrition based on global leadership initiative in malnutrition criteria for completeness of diagnosis and future risk of malnutrition based on current malnutrition diagnosis: systematic review and meta-analysis. *Front Nutr* 2023;10: 1174945.
- [15] Sánchez-Rodríguez D, De Meester D, Minon L, Claessens M, Güntüs N, Lietsen S, et al. Association between malnutrition assessed by the global leadership initiative on malnutrition criteria and mortality in older people: a scoping review. *Int J Environ Res Publ Health* 2023;20:5320.
- [16] Brown D, Loeliger J, Stewart J, Graham KL, Goradia S, Serges C, et al. Relationship between global leadership initiative on malnutrition (GLIM) defined malnutrition and survival, length of stay and post-operative complications in people with cancer: a systematic review. *Clin Nutr* 2023;42:255–68.
- [17] Yin L, Chong F, Huo Z, Li N, Liu J, Xu H. GLIM-Defined malnutrition and overall survival in cancer patients: a meta-analysis. *J Parenter Enteral Nutr* 2023;vol. 47:207–19.
- [18] Lidoriki I, Frountzas M, Mela E, Papaconstantinou D, Vilas M, Sotiropoulou M, et al. The prognostic role of GLIM criteria in postoperative outcomes after upper gastrointestinal cancer surgery: a meta-analysis of observational studies. *Nutr Cancer* 2023;75:640–51.
- [19] Matsui R, Rifu K, Watanabe J, Inaki N, Fukunaga T. Impact of malnutrition as defined by the GLIM criteria on treatment outcomes in patients with cancer: a systematic review and meta-analysis. *Clin Nutr* 2023;42:615–24.
- [20] Peng D, Zong K, Yang H, Huang Z, Mou T, Jiang P, et al. Malnutrition diagnosed by the global leadership initiative on malnutrition criteria predicting survival and clinical outcomes of patients with cancer: a systematic review and meta-analysis. *Front Nutr* 2022;9:1053165.
- [21] Xu J, Jie Y, Sun Y, Gong D, Fan Y. Association of global leadership initiative on malnutrition with survival outcomes in patients with cancer: a thematic review and meta-analysis. *Clin Nutr* 2022;41:1874–80.
- [22] Personal communication. Malone A. Implementation of GLIM – Facilitators and obstacles. Presented at the 45th ESPEN 2023 congress on clinical nutrition and metabolism, [Lyon, France].

- [23] Personal communication. Harriet Jager-Wittenaar. GLIM implementation in practice and research. <https://european-nutrition.org/wp-content/uploads/2023/06/Harriet-Jager-ONCA-GLIM-Implementation.pdf>.
- [24] Bauer MS, Kirchner J. Implementation science: what is it and why should I care? *Psychiatry Res* 2020;283:112376.
- [25] Rothenberg E, Tsagari A, Erickson N, Katsagoni CN, Malone A, de van der Schueren M, et al. Global leadership initiative on malnutrition (GLIM) for the diagnosis of malnutrition – a framework for consistent dietetic practice. *Clin Nutr ESPEN* 2024;60:261–5.
- [26] Personal communication. Winkler M. Incorporating GLIM with the Academy/ASPEN malnutrition diagnostic approach. Presented at the ASPEN 2024 Nutrition Science and Practice Conference, Tampa, FL.
- [27] Notification of the FY2024 medical fee revision by ministry of health, labor and welfare of Japan; https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000196352_00012.html (<https://www.mhlw.go.jp/content/12400000/001251533.pdf>).
- [28] WHO integrated brief interventions for non-communicable disease risk factors in primary care: the manual. BRIEF project. Copenhagen: WHO Regional Office for Europe; 2022. License: CC BY-NC-SA 3.0 IGO.
- [29] World Health Organization. Regional Office for Europe. Disease-related malnutrition: a time for action. <https://iris.who.int/handle/10665/375033>; 2023.
- [30] WHO tuberculosis and malnutrition factsheet (who.int)/<https://www.who.int/europe/publications/m/item/tuberculosis-and-malnutrition-factsheet> (April 2024).
- [31] de van der Schueren MAE, Jager-Wittenaar H. Malnutrition risk screening: new insights in a new era. *Clin Nutr* 2022;41:2163–8.
- [32] Jager-Wittenaar H, Sealy M, Naumann E, de van der Schueren M. Nutritional risk screening: a need to guide alic in nutritionland. *Curr Opin Clin Nutr Metab Care* 2024;27:381–6.
- [33] Power L, Mullaly D, Gibney ER, Clarke M, Visser M, Volkert D, et al. A review of the validity of malnutrition screening tools used in older adults in community and healthcare settings – a MaNuEL study. *Clin Nutr ESPEN* 2018;24:1–13.
- [34] Cortés-Aguilar R, Malih N, Abbate M, Fresneda S, Yañez A, Bannasar-Veny M. Validity of nutrition screening tools for risk of malnutrition among hospitalized adult patients: a systematic review and meta-analysis. *Clin Nutr* 2024;43:1094–116.
- [35] García-Fuente I, Corral-Gudino L, Gabella-Martín M., E Olivet-de-la-Fuente VE, Pérez-Nieto J, Miramontes-González P., et al. How to detect non-institutionalized older patients at risk of malnutrition during their hospitalization? Comparison of 8 screening tools for malnutrition or nutritional risk. *Rev Clin Esp* 2024;S2254–8874(24):00041-9.
- [36] Wang Y, Liu Z, Zhang H et al. Evaluation of different screening tools as the first step of the GLIM framework: a cross-sectional study of Chinese cancer patients in an outpatient setting. *Nutr Clin Pract* 39:702–713.
- [37] Van Dronkelaar C, Tieland M, Cederholm T, Reijnierse EM, Weijts PJM, Kruijenga H. Malnutrition screening tools are not sensitive enough to identify older hospital patients with malnutrition. *Nutrients* 2023;15:5126.
- [38] Henriksen C, Paur I, Pedersen A, Kværner AS, Ræder H, Henriksen HB, et al. Agreement between GLIM and PG-SGA for diagnosis of malnutrition depends on the screening tool used in GLIM. *Clin Nutr* 2022;41:329–36.
- [39] Barazzoni R, Sulz I, Schindler K, Bischoff SC, Gortan Cappellari G, Hiesmayr M, Nutrition Day Research Group. A negative impact of recent weight loss on in-hospital mortality is not modified by overweight and obesity. *Clin Nutr* 2020;39:2510–6.
- [40] Barazzoni R, Jensen GL, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the global leadership initiative on malnutrition (GLIM) diagnosis of malnutrition. *Clin Nutr* 2022;14:1025–32.
- [41] Compher C, Cederholm T, Correia MITD, Gonzalez MC, Higashiguchi T, Shi HP, et al. Guidance for assessment of the muscle mass phenotypic criterion for the global leadership initiative on malnutrition diagnosis of malnutrition. *J Parenter Enteral Nutr* 2022;vol. 46:1232–42.
- [42] Huber FA, Del Grande F, Rizzo S, Guglielmi G, Guggenberger R. MRI in the assessment of adipose tissues and muscle composition: how to use it. *Quant Imag Med Surg* 2020;10:1636–49.
- [43] Cruz-Jentoft AJ, Gonzalez MC, Prado CM. Sarcopenia ≠ low muscle mass. *Eur Geriatr Med* 2023;14:225–8.
- [44] Gonzalez MC, Mehrnezhad A, Razaviarab N, Barbosa-Silva TG, Heymsfield SB. Calf circumference: cutoff values from the NHANES 1999–2006. *Am J Clin Nutr* 2021;113:1679–87.
- [45] Jensen B, Braun W, Geisler C, Both M, Klückmann K, Müller MJ, et al. Limitations of fat-free mass for the assessment of muscle mass in obesity. *Obes Facts* 2019;12:307–15.
- [46] Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. *Clin Nutr* 2022;41:990–1000.
- [47] Kirk B, Cawthon PM, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, et al., for the Global Leadership Initiative in Sarcopenia (GLIS) group. The conceptual definition of sarcopenia: Delphi consensus from the global leadership initiative in sarcopenia (GLIS). *Age Ageing* 2024;53(3):afae052.
- [48] Morley JE, Thomas DR. Anorexia and aging: pathophysiology. *Nutrition* 1999;15:499–503.
- [49] Jensen GL, Cederholm T, Ballesteros-Pomar MD, Blaauw R, Correia MITD, Cuesta C, et al. Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: a modified Delphi approach. *J Parenter Enteral Nutr* 2024;vol. 48:145–54.
- [50] Cederholm T, Jensen GL, Ballesteros-Pomar MD, Blaauw R, Correia MITD, Cuesta C, et al. Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: a modified Delphi approach. *Clin Nutr* 2024;43:1025–32.
- [51] Cederholm T, Rothenberg E, Barazzoni R. A clinically relevant diagnosis code for “Malnutrition in adults” is needed in ICD-11. *J Nutr Health Aging* 2022;26:314–5.
- [52] Heymsfield SB, Brown J, Ramirez S, Prado CM, Tinsley GM, Gonzalez MC. Are lean body mass and fat-free mass the same or different body components? A critical perspective. *Adv Nutr* 2024;15:100335. <https://doi.org/10.1016/j.advnut.2024.100335>.
- [53] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;48:16–31.
- [54] Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA. Total and appendicular lean mass reference ranges for Australian men and women: the Geelong osteoporosis study. *Calcif Tissue Int* 2014;94:363–72.
- [55] Chen LK, Lee WJ, Peng LN, Liu LK, Arai H, Akishita M, et al. Recent advances in sarcopenia research in Asia: 2016 update from the Asian working group for sarcopenia. *J Am Med Dir Assoc* 2016;17:767 e1–e7.
- [56] Tanimoto Y, Watanabe M, Sun W, Hirota C, Sugiura Y, Kono R, et al. Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. *Arch Gerontol Geriatr* 2012;54:e230–3.
- [57] Cheng Q, Zhu X, Zhang X, Li H, Du Y, Hong W, et al. A cross-sectional study of loss of muscle mass corresponding to sarcopenia in healthy Chinese men and women: reference values, prevalence, and association with bone mass. *J Bone Miner Metabol* 2014;32:78–88.
- [58] Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition – an ESPEN consensus statement. *Clin Nutr* 2015;34:335–40.
- [59] Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18–98 y. *J Intern Ass Study Obesity* 2002;26:953–60.
- [60] Levine ME, Crimmins EM. The impact of insulin resistance and inflammation on the association between sarcopenic obesity and physical functioning. *Obesity* 2012;20:2101–6.
- [61] Pasco JA, Holloway-Kew KL, Tembo MC, Sui SX, Anderson KB, Rufus-Membere P, et al. Normative data for lean mass using FNIH criteria in an Australian setting. *Calcif Tissue Int* 2019;104:475–9.